Free Trial
→ M.A.G.A. is Finished – This Could be even Better (From Paradigm Press) (Ad)

Analysts Say These 2 Mid-Cap Biotechs Have 2x Potential

Written by MarketBeat Staff
May 18, 2023

Key Points

  • Biotech stocks have a reputation for being high risk, high reward.
  • Many of the stocks Wall Street thinks can double (or better) over the next 12 months are biotechs.
  • Although Denali has yet to commercialize a product, analysts are encouraged by its progress and collaborations with major biopharmaceutical players.
  • Since its May 4th report, seven analysts have reiterated buy ratings on Ultragenyx compared to one hold.
  • MarketBeat previews the top five stocks to own by May 1st.

unlock icon  Upgrade Now

This premium article is available to MarketBeat All Access subscribers only. Log in to your account or sign up below.

Upgrade Now See Benefits

Already have an account? Log in here.

Should You Invest $1,000 in Denali Therapeutics Right Now?

Before you consider Denali Therapeutics, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Denali Therapeutics wasn't on the list.

While Denali Therapeutics currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

Metaverse Stocks And Why You Can't Ignore Them Cover
Metaverse Stocks And Why You Can't Ignore Them

Thinking about investing in Meta, Roblox, or Unity? Enter your email to learn what streetwise investors need to know about the metaverse and public markets before making an investment.

Get This Free Report
Like this article? Share it with a colleague.

Companies Mentioned in This Article

CompanyMarketRank™Current PricePrice ChangeDividend YieldP/E RatioConsensus RatingConsensus Price Target
Denali Therapeutics (DNLI)
4.1185 of 5 stars		$16.60+0.6%N/A-6.01Buy$37.57
Ultragenyx Pharmaceutical (RARE)
4.3442 of 5 stars		$38.91+2.2%N/A-6.14Moderate Buy$92.79
Sarepta Therapeutics (SRPT)
4.6745 of 5 stars		$62.12+2.1%N/A49.70Moderate Buy$158.70
Pfizer (PFE)
4.9688 of 5 stars		$24.26+2.0%7.09%17.21Moderate Buy$29.64
Exelixis (EXEL)
3.9836 of 5 stars		$38.71+0.4%N/A21.87Moderate Buy$37.59
Moderna (MRNA)
4.4992 of 5 stars		$28.19+1.3%N/A-3.04Hold$58.70
United Therapeutics (UTHR)
4.9001 of 5 stars		$295.62-1.7%N/A12.98Moderate Buy$390.17
Biogen (BIIB)
4.6806 of 5 stars		$120.74+0.5%N/A10.79Hold$201.93
Sanofi (SNY)
3.4063 of 5 stars		$54.74+1.9%2.92%21.98Buy$63.33
Eli Lilly and Company (LLY)
4.9079 of 5 stars		$895.78+1.2%0.67%76.50Moderate Buy$1,000.32
Compare These Stocks  Add These Stocks to My Watchlist 

Featured Articles and Offers

7 Inflation-Proof Stocks to Protect Your Portfolio
February 5, 2025

7 Inflation-Proof Stocks to Protect Your Portfolio

Inflation is sticking around—is your portfolio ready? In this video, we break down 7 stocks that could help shield your investments from inflation’s impact.

Watch Video

Recent Videos

3 Stocks Offering Rare Generational Buying Opportunities
Make Your Money Work Harder: The Power of Dividend Investing
7 Cybersecurity Stocks Outperforming the Market Right Now

Stock Lists

All Stock Lists

Investing Tools

Calendars and Tools

Search Headlines